![]() ![]() The data presented on this page does not represent the view of Endo Pharmaceuticals Inc and its employees or that of Zippia.Įndo Pharmaceuticals Inc may also be known as or be related to ENDO HEALTH SOLUTIONS INC., Endo Health Solutions Inc, Endo Health Solutions Inc., Endo International plc, Endo Pharmaceuticals and Endo Pharmaceuticals Inc. None of the information on this page has been provided or approved by Endo Pharmaceuticals Inc. Use the PitchBook Platform to explore the full. I am the EVP, Global R&D for Endo Pharmaceuticals, leading Clinical Research and Development, Medical and Regulatory Affairs.Throughout my career, I’ve demonstrated success in the. ![]() ![]() While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Information on stock, financials, earnings, subsidiaries, investors, and executives for Endo Pharmaceuticals. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. The employee data is based on information from people who have self-reported their past or current employments at Endo Pharmaceuticals Inc. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.Zippia gives an in-depth look into the details of Endo Pharmaceuticals Inc, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Endo Pharmaceuticals Inc. However, Teva prevailed in this acquisition with a substantially higher bid.OpioidsEndo is one of the companies named in lawsuits by the states of Ohio, Missouri and Mississippi as responsible for the US opioid epidemic. The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion.In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.Acquisition attemptsIn early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. See More cals to diversify into endocrinology and oncology. REUTERS/Brian Snyder/File Photo Companies Law Firms Endo International PLC Aug 16 (Reuters) - Endo International Plc (ENDP.O) filed for bankruptcy on Tuesday after reaching a 6. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.AcquisitionsIn 2009, Endo bought Indevus Pharmaceuti. 23 Salaries 27 Q&A Interviews 4 Photos ENDO INTERNATIONAL PLC Careers and Employment Work wellbeing Results based on 43 responses to Indeeds work wellbeing survey. Endo International plc is a global specialty pharmaceutical company focused on improving patients’ lives while creating value.Įndo International plc is a generics and specialty branded pharmaceutical company. ![]()
0 Comments
Leave a Reply. |